Sign In
Buy OGN
$13.40
+0.0200 (+0.149%)
At Close: Jun 03, 2026
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon
08:25am, Thursday, 03'rd Jul 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Organon To Contact Him Directly To Discuss Their Options If you purchased or acquir
Karolinska Development receives update from Organon concerning OG-6219
01:00am, Thursday, 03'rd Jul 2025
STOCKHOLM, SWEDEN – July 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces an update from Organon on the development of the drug candidate OG-6219, acquired by Organon thro
NEW ORLEANS, July 02, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 22, 2025 to file lead plaintiff applications in a securi
The Gross Law Firm Reminds Organon & Co. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2025 – OGN
04:02pm, Wednesday, 02'nd Jul 2025
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Organon & Co. (NYSE: OGN). Shareholders who purchased shares of OGN during the class perio
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon
11:15am, Wednesday, 02'nd Jul 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Organon To Contact Him Directly To Discuss Their Options
NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Organon & Co. ("Organon" or the "Company") (NYSE: OGN). Such investors are advise
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company'
Organon to halt development of endometriosis pain drug after mid-stage trial failure
08:01am, Wednesday, 02'nd Jul 2025
Organon said on Wednesday it will discontinue the development of its experimental drug, after it failed to reduce pain in women suffering from endometriosis in a mid-stage study.
Organon Provides Update on Phase 2 ELENA Proof-of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain
07:30am, Wednesday, 02'nd Jul 2025
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a focus on women's health, today announced that the Phase 2 ELENA proof-of-concept study evaluating the invest
NEW YORK and NEW ORLEANS, July 01, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they h
OGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit
02:10pm, Tuesday, 01'st Jul 2025
NEW YORK , July 1, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Organon & Co. (NYSE: OGN) between October 31, 2024 and April 30, 202
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Organon & Co. (NYSE: OGN) between October 31, 2024 and April 30
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Organon & Co. (“Organon” or the “Company”) (NYSE: OGN). Such investors
Organon & Co. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - OGN
09:00am, Tuesday, 01'st Jul 2025
NEW YORK , July 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Organon & Co. ("Organon" or the "Company") (NYSE: OGN) of a class action securities lawsuit. CLASS DEFINITION: The
SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Organon & Co. (NYSE: OGN) securi
